Over a month ago
Conference/Events
Virtual Meeting to be…
Virtual Meeting to be held on December 14 hosted by Barrington.
Show Hide Related Items >> <<
CCRN Cross Country Healthcare 12/13/22 Cross Country Healthcare completes acquisition of Hireup Leadership 09/14/22 Cross Country Healthcare sees path to $3B in revenue, $300M in EBITDA 09/13/22 Cross Country Healthcare to acquire Mint Medical Physician Staffing, LP 08/16/22 Cross Country Healthcare board authorizes up to $100M share repurchase program CCRN Cross Country Healthcare 11/07/22 Barrington Cross Country Healthcare price target raised to $45 from $41 at Barrington 10/05/22 Truist Cross Country Healthcare downgraded to Hold at Truist on valuation 10/05/22 Truist Cross Country Healthcare downgraded to Hold from Buy at Truist 09/15/22 Benchmark Cross Country Healthcare price target raised to $42 from $37 at Benchmark CCRN Cross Country Healthcare 11/02/22 Cross Country Healthcare sees Q4 adjusted EPS 85c-95c, consensus 74c 11/02/22 Cross Country Healthcare reports Q3 adjusted EPS $1.07, consensus 95c 09/14/22 Cross Country Healthcare sees Q4 revenue minimum $550M, consensus $519.55M 09/14/22 Cross Country Healthcare sees minimum 2023 revenue $2.2B, consensus $2.07B CCRN Cross Country Healthcare 09/14/22 What You Missed On Wall Street On Wednesday 09/14/22 What You Missed On Wall Street This Morning 08/03/22 Fly Intel: After-Hours Movers
Hot Stocks
Cross Country Healthcare…
Cross Country Healthcare "announced the acquisition of Hireup Leadership Inc. Hireup partners with organizations, including hospitals, academic medical centers, and clinics, to recruit healthcare leaders within nursing, allied, physician, human resources, and finance."
Show Hide Related Items >> <<
CCRN Cross Country Healthcare 09/14/22 Cross Country Healthcare sees path to $3B in revenue, $300M in EBITDA 09/13/22 Cross Country Healthcare to acquire Mint Medical Physician Staffing, LP 08/16/22 Cross Country Healthcare board authorizes up to $100M share repurchase program CCRN Cross Country Healthcare 11/07/22 Barrington Cross Country Healthcare price target raised to $45 from $41 at Barrington 10/05/22 Truist Cross Country Healthcare downgraded to Hold at Truist on valuation 10/05/22 Truist Cross Country Healthcare downgraded to Hold from Buy at Truist 09/15/22 Benchmark Cross Country Healthcare price target raised to $42 from $37 at Benchmark CCRN Cross Country Healthcare 11/02/22 Cross Country Healthcare sees Q4 adjusted EPS 85c-95c, consensus 74c 11/02/22 Cross Country Healthcare reports Q3 adjusted EPS $1.07, consensus 95c 09/14/22 Cross Country Healthcare sees Q4 revenue minimum $550M, consensus $519.55M 09/14/22 Cross Country Healthcare sees minimum 2023 revenue $2.2B, consensus $2.07B CCRN Cross Country Healthcare 09/14/22 What You Missed On Wall Street On Wednesday 09/14/22 What You Missed On Wall Street This Morning 08/03/22 Fly Intel: After-Hours Movers
Conference/Events
Analyst Tanquilut to hold…
Analyst Tanquilut to hold a group dinner meeting in New York on December 6 at 6 pm hosted by Jefferies.
Show Hide Related Items >> <<
CCRN Cross Country Healthcare 09/14/22 Cross Country Healthcare sees path to $3B in revenue, $300M in EBITDA 09/13/22 Cross Country Healthcare to acquire Mint Medical Physician Staffing, LP 08/16/22 Cross Country Healthcare board authorizes up to $100M share repurchase program CCRN Cross Country Healthcare 11/07/22 Barrington Cross Country Healthcare price target raised to $45 from $41 at Barrington 10/05/22 Truist Cross Country Healthcare downgraded to Hold at Truist on valuation 10/05/22 Truist Cross Country Healthcare downgraded to Hold from Buy at Truist 09/15/22 Benchmark Cross Country Healthcare price target raised to $42 from $37 at Benchmark CCRN Cross Country Healthcare 11/02/22 Cross Country Healthcare sees Q4 adjusted EPS 85c-95c, consensus 74c 11/02/22 Cross Country Healthcare reports Q3 adjusted EPS $1.07, consensus 95c 09/14/22 Cross Country Healthcare sees Q4 revenue minimum $550M, consensus $519.55M 09/14/22 Cross Country Healthcare sees minimum 2023 revenue $2.2B, consensus $2.07B CCRN Cross Country Healthcare 09/14/22 What You Missed On Wall Street On Wednesday 09/14/22 What You Missed On Wall Street This Morning 08/03/22 Fly Intel: After-Hours Movers
Conference/Events
Virtual Meeting to be…
Virtual Meeting to be held on December 14 hosted by Barrington.
Show Hide Related Items >> <<
CCRN Cross Country Healthcare 09/14/22 Cross Country Healthcare sees path to $3B in revenue, $300M in EBITDA 09/13/22 Cross Country Healthcare to acquire Mint Medical Physician Staffing, LP 08/16/22 Cross Country Healthcare board authorizes up to $100M share repurchase program CCRN Cross Country Healthcare 11/07/22 Barrington Cross Country Healthcare price target raised to $45 from $41 at Barrington 10/05/22 Truist Cross Country Healthcare downgraded to Hold at Truist on valuation 10/05/22 Truist Cross Country Healthcare downgraded to Hold from Buy at Truist 09/15/22 Benchmark Cross Country Healthcare price target raised to $42 from $37 at Benchmark CCRN Cross Country Healthcare 11/02/22 Cross Country Healthcare sees Q4 adjusted EPS 85c-95c, consensus 74c 11/02/22 Cross Country Healthcare reports Q3 adjusted EPS $1.07, consensus 95c 09/14/22 Cross Country Healthcare sees Q4 revenue minimum $550M, consensus $519.55M 09/14/22 Cross Country Healthcare sees minimum 2023 revenue $2.2B, consensus $2.07B CCRN Cross Country Healthcare 09/14/22 What You Missed On Wall Street On Wednesday 09/14/22 What You Missed On Wall Street This Morning 08/03/22 Fly Intel: After-Hours Movers
Conference/Events
Analyst Tanquilut to hold…
Analyst Tanquilut to hold a group dinner meeting in New York on December 6 at 6 pm hosted by Jefferies.
Show Hide Related Items >> <<
CCRN Cross Country Healthcare 09/14/22 Cross Country Healthcare sees path to $3B in revenue, $300M in EBITDA 09/13/22 Cross Country Healthcare to acquire Mint Medical Physician Staffing, LP 08/16/22 Cross Country Healthcare board authorizes up to $100M share repurchase program CCRN Cross Country Healthcare 11/07/22 Barrington Cross Country Healthcare price target raised to $45 from $41 at Barrington 10/05/22 Truist Cross Country Healthcare downgraded to Hold at Truist on valuation 10/05/22 Truist Cross Country Healthcare downgraded to Hold from Buy at Truist 09/15/22 Benchmark Cross Country Healthcare price target raised to $42 from $37 at Benchmark CCRN Cross Country Healthcare 11/02/22 Cross Country Healthcare sees Q4 adjusted EPS 85c-95c, consensus 74c 11/02/22 Cross Country Healthcare reports Q3 adjusted EPS $1.07, consensus 95c 09/14/22 Cross Country Healthcare sees Q4 revenue minimum $550M, consensus $519.55M 09/14/22 Cross Country Healthcare sees minimum 2023 revenue $2.2B, consensus $2.07B CCRN Cross Country Healthcare 09/14/22 What You Missed On Wall Street On Wednesday 09/14/22 What You Missed On Wall Street This Morning 08/03/22 Fly Intel: After-Hours Movers
Conference/Events
31st Annual Healthcare…
31st Annual Healthcare Conference to be held in Rancho Palos Verdes, CA on November 7-10.
Show Hide Related Items >> <<
10/31/22 United Therapeutics reports preliminary analysis from EXPEDITE study 10/27/22 Liquidia announces POP panel denies UTC request for review of IPR decsion 10/11/22 United Therapeutics enrolls first patient in phase 3 TETON 2 study 09/21/22 United Therapeutics announces termination of PERFECT clinical study of Tyvaso TOI The Oncology Institute 10/11/22 The Oncology Institute appoints Phil Reger as CIO 10/06/22 The Oncology Institute expands into South Florida 09/29/22 The Oncology Institute enrolls first patients in Phase 3 trial of pirtobrutinib 09/12/22 The Oncology Institute becomes certified as a Patient Safety Organization 09/08/22 Tandem Diabetes CFO says 'goal is always to beat' guidance 09/08/22 Tandem Diabetes CEO saw 'positive shift,' start of 'momentum build' in August 08/18/22 Tandem Diabetes achieves milestone of 1M insulin boluses delivered using app 07/21/22 Tandem Diabetes acquires Capillary Biomedical, terms not disclosed 10/21/22 Tenet Healthcare falls -31.7% 10/21/22 Tenet Healthcare falls -29.4% 10/21/22 Tenet Healthcare falls -26.0% 10/20/22 Tenet Healthcare drops 17% to $45.00 after Q4 guidance misses estimates 11/02/22 Protagonist Therapeutics names Arturo Molina as Chief Medical Officer 10/24/22 Sutro Biopharma announces departure of Chief Medical Officer 08/08/22 Sutro Biopharma sees projected cash runway into 1H24 07/26/22 Sutro:1st patient dosed in study with Merck for cytokine derivative for cancer 06/28/22 Pfizer and Roivant Sciences unveil Priovant Therapeutics 05/24/22 Dermavant Sciences announces FDA approval of VTAMA cream, 1% 05/16/22 Aruvant announces oral presentation on ARU-1801 10/11/22 Avidity Biosciences announces Phase1/2 Explore 44 clinical trial 09/27/22 Avidity Biosciences drops 20% after FDA partial clinical hold on MARINA trial 09/27/22 Avidity: Partial clinical hold due to SAE reported in single participant 09/27/22 Avidity Biosciences announces FDA partial clinical hold on trial enrollment MGTA Magenta Therapeutics 11/03/22 Magenta Therapeutics to present MGTA-117 data at 2022 ASH meeting 11/03/22 Magenta Therapeutics expects cash to fund operations into Q2 of 2024 11/03/22 Magenta Therapeutics to present data at 2022 ASH meeting 08/17/22 Magenta Therapeutics appoints Vasconcelles to board of directors 11/07/22 Kamada provides update on progress in Phase 3 trial of inhaled AAT 10/19/22 Kamada awarded $22M extension of Canadian supply tender 07/15/22 Kamada announces resolution to the labor strike at facility in Israel 07/06/22 Kamada secures $11.4M international Varizig procurement agreement 11/07/22 Avalo sells economic rights to previously out-licensed assets for $5M 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 11/01/22 J&J: Abiomed acquisition has enterprise value of $16.6B 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 09/28/22 Iqvia Decentralized Clinical Trial program achieves independent GDPR validation 08/15/22 Third Point adds Disney, exits Intuit in Q2 08/08/22 GSK, IQVIA launch Vaccine Track platform 06/07/22 Iqvia appoints Mack as Chief Scientific Officer of RWS GLUE Monte Rosa Therapeutics 11/01/22 Monte Rosa announces first patient dosed in phase 1/2 trial of MRT-2359 09/06/22 Monte Rosa Therapeutics announces FDA cleared IND for MRT-2359 08/11/22 Monte Rosa Therapeutics sees cash funding operations into late 2024 05/11/22 Monte Rosa Therapeutics sees cash, equivalents funding operations into late 2024 FULC Fulcrum Therapeutics 11/07/22 Fulcrum appoints new Chief Medical and new Chief Scientific officers 10/20/22 Fulcrum Therapeutics reports resignation of president of R&D 10/12/22 Fulcrum Therapeutics to present data from OLE portion of Phase 2 ReDUX4 study 08/11/22 Fulcrum Therapeutics expects cash to fund operations into mid-2024 07/28/22 Community Health trading resumes 07/28/22 Community Health trading halted, volatility trading pause 07/22/22 Community Health rises 22.2% 07/22/22 Community Health rises 14.1% 11/02/22 Cullinan appoints Ryan to board of directors 10/25/22 Cullinan increases ownership stake in its MICA subsidiary 08/15/22 Cullinan announces Jacquelyn Sumer as chief legal officer 08/10/22 Cullinan expects cash to fund operations through 2026 CCRN Cross Country Healthcare 09/14/22 Cross Country Healthcare sees path to $3B in revenue, $300M in EBITDA 09/13/22 Cross Country Healthcare to acquire Mint Medical Physician Staffing, LP 08/16/22 Cross Country Healthcare board authorizes up to $100M share repurchase program 10/26/22 Candel Therapeutics partners with Penn to study novel viral immunotherapies 09/15/22 Candel Therapeutics receives orphan drug designation for CAN--2409 09/07/22 Candel Therapeutics appoints Jason Amello as CFO, Garrett Nichols as CMO 08/01/22 Candel Therapeutics appoints three new members to board of directors $404.17 / +23.57 (+6.19%)
10/10/22 Qiagen up 5%, Bio-Rad down 6% following WSJ report on talks to combine 08/03/22 Bio-Rad acquires Curiosity Diagnostics for total consideration of up to $170M 07/28/22 Bio-Rad increases stock buyback authorization by $200M 06/27/22 Bio-Rad publishes corporate sustainability report 09/14/22 Amwell appoints Matthew McAllister as Chief Product Officer 08/25/22 Teladoc, Amwell rise after Amazon says will shut down Amazon Care 06/14/22 Amwell falls -8.6% 06/08/22 Amwell appoints Nelson as Chief Medical Officer 11/02/22 Absci appoints Rabinovitsj to board of directors 10/04/22 Absci appoints Andreas Busch as Chief Innovation Officer 07/14/22 Absci hires Dettore as Chief People Officer, Gold as Chief Marketing Officer 07/07/22 Absci enters multi-program collaboration with biotech partner 08/12/22 JPMorgan Absci double downgraded to Underweight at JPMorgan on slower revenue ramp 08/12/22 JPMorgan Absci downgraded to Underweight from Overweight at JPMorgan 08/12/22 Cowen Absci upgraded to Outperform from Market Perform at Cowen 07/18/22 Truist Truist starts Absci at Buy on confluence of biotech, next-gen biologics 08/04/22 Citi Community Health price target lowered to $6 from $14 at Citi 07/29/22 Oppenheimer Community Health price target lowered to $6 from $16 at Oppenheimer 06/16/22 Loop Capital Loop starts Community Health at Hold amid labor challenges 06/16/22 Loop Capital Community Health initiated with a Hold at Loop Capital 10/27/22 Credit Suisse Iqvia price target lowered to $265 from $300 at Credit Suisse 10/27/22 Citi Iqvia price target lowered to $275 from $290 at Citi 10/27/22 Barclays Iqvia price target raised to $235 from $215 at Barclays 10/18/22 Deutsche Bank Iqvia price target lowered to $270 from $290 at Deutsche Bank 09/27/22 Chardan Avidity Biosciences price target lowered to $27 from $29 at Chardan 07/20/22 Chardan Avidity Biosciences initiated with a Buy at Chardan 07/11/22 Raymond James Avidity Biosciences initiated with a Strong Buy at Raymond James 10/27/22 JPMorgan Roivant Sciences initiated with an Overweight at JPMorgan 08/16/22 Citi Roivant Sciences price target raised to $10 from $9 at Citi 05/23/22 SVB Securities Roivant Sciences initiated with an Outperform at SVB Leerink 04/29/22 Cantor Fitzgerald Roivant Sciences initiated with an Overweight at Cantor Fitzgerald 11/02/22 Morgan Stanley Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/22 Deutsche Bank Abiomed downgraded to Hold from Buy at Deutsche Bank 11/01/22 Piper Sandler Abiomed downgraded to Neutral from Overweight at Piper Sandler 11/01/22 Cowen Cowen starts Legend Biotech with an Outperform on Carvykti potential MGTA Magenta Therapeutics 08/24/22 Goldman Sachs Magenta downgraded on limited clinical catalysts at Goldman Sachs 08/24/22 Goldman Sachs Magenta Therapeutics downgraded to Neutral from Buy at Goldman Sachs 04/18/22 Mizuho Magenta Therapeutics price target lowered to $8 from $17 at Mizuho 04/18/22 BTIG Magenta Therapeutics price target lowered to $6 from $10 at BTIG 11/09/22 H.C. Wainwright Sutro Biopharma price target lowered to $20 from $30 at H.C. Wainwright 08/23/22 Truist Sutro Biopharma price target lowered to $21 from $37 at Truist 08/18/22 Wells Fargo Sutro Biopharma assumed with an Overweight at Wells Fargo 06/28/22 Piper Sandler Sutro Biopharma price target raised to $16 from $14 at Piper Sandler 10/27/22 Raymond James Tenet Healthcare price target lowered to $80 from $135 at Raymond James 10/25/22 Citi Tenet Healthcare shares offer 'significant upside,' says Citi 10/24/22 Truist Tenet Healthcare price target lowered to $55 from $80 at Truist 10/24/22 Deutsche Bank Tenet Healthcare price target lowered to $48 from $90 at Deutsche Bank 11/03/22 Lake Street Tandem Diabetes price target lowered to $60 from $150 at Lake Street 11/03/22 Craig-Hallum Tandem Diabetes price target lowered to $80 from $105 at Craig-Hallum 11/03/22 Cowen Tandem Diabetes price target lowered to $61 from $107 at Cowen 11/03/22 Baird Tandem Diabetes price target lowered to $45 from $76 at Baird TOI The Oncology Institute 09/14/22 Guggenheim The Oncology Institute initiated with a Buy at Guggenheim 08/15/22 Jefferies The Oncology Institute initiated with a Buy at Jefferies 11/03/22 Wedbush United Therapeutics price target raised to $305 from $250 at Wedbush 11/03/22 Oppenheimer United Therapeutics price target raised to $375 from $325 at Oppenheimer 11/03/22 H.C. Wainwright United Therapeutics price target raised to $300 from $255 at H.C. Wainwright 10/11/22 Morgan Stanley United Therapeutics initiated with an Overweight at Morgan Stanley CCRN Cross Country Healthcare 11/07/22 Barrington Cross Country Healthcare price target raised to $45 from $41 at Barrington 10/05/22 Truist Cross Country Healthcare downgraded to Hold at Truist on valuation 10/05/22 Truist Cross Country Healthcare downgraded to Hold from Buy at Truist 09/15/22 Benchmark Cross Country Healthcare price target raised to $42 from $37 at Benchmark FULC Fulcrum Therapeutics 11/08/22 Piper Sandler Fulcrum Therapeutics price target lowered to $18 from $42 at Piper Sandler 10/20/22 Stifel Fulcrum Therapeutics price target lowered to $35 from $43 at Stifel 06/10/22 Piper Sandler Fulcrum should be bought on today's selloff, says Piper Sandler 06/10/22 H.C. Wainwright H.C. Wainwright says Fulcrum data 'raises multiple questions,' halves target 03/31/22 BMO Capital Candel Therapeutics price target lowered to $12 from $18 at BMO Capital 11/18/21 BMO Capital Candel Therapeutics initiated with an Outperform at BMO Capital $404.17 / +23.57 (+6.19%)
10/11/22 Jefferies Jefferies 'not surprised' by report of Bio-Rad talks to combine with Qiagen 08/24/22 Credit Suisse Bio-Rad initiated with an Outperform at Credit Suisse 07/08/22 Citi Bio-Rad price target lowered to $700 from $750 at Citi 05/02/22 Citi Bio-Rad price target lowered to $750 from $800 at Citi 09/07/22 Truist Amwell initiated with a Hold at Truist 09/07/22 Piper Sandler Amwell price target lowered to $5 from $6 at Piper Sandler 06/23/22 Piper Sandler Amwell price target raised to $6 from $5 at Piper Sandler 06/03/22 Morgan Stanley CVS deal a 'game-changer' for Amwell's Converge, says Morgan Stanley GLUE Monte Rosa Therapeutics 10/13/22 UBS Monte Rosa Therapeutics initiated with a Buy at UBS 08/15/22 Jefferies Monte Rosa Therapeutics initiated with a Buy at Jefferies 05/11/22 Piper Sandler Monte Rosa Therapeutics price target lowered to $21 from $40 at Piper Sandler 04/28/22 Credit Suisse Monte Rosa Therapeutics initiated with a Neutral at Credit Suisse 11/02/22 United Therapeutics reports Q3 EPS $4.91, consensus $3.89 08/03/22 United Therapeutics reports Q2 EPS $2.41, consensus $4.12 TOI The Oncology Institute 08/09/22 The Oncology Institute reports Q2 EPS (6c) vs. (5c) last year 11/02/22 Tandem Diabetes cuts FY22 revenue view to $800M-$805M, consensus $836.4M 11/02/22 Tandem Diabetes reports Q3 EPS (76c), consensus (5c) 08/03/22 Tandem Diabetes cuts FY22 revenue view to $835M-$845 from $850M-$865M 08/03/22 Tandem Diabetes reports Q2 EPS (24c), consensus 2c 10/20/22 Tenet narrows FY22 EPS view to $5.88-$6.42 from $5.80-$7, consensus $6.46 10/20/22 Tenet Healthcare sees Q4 adjusted EPS $1.00-$1.54, consensus $1.80 10/20/22 Tenet Healthcare reports Q3 adjusted EPS $1.44, consensus $1.24 10/20/22 Notable companies reporting after market close 11/08/22 Sutro Biopharma reports Q3 EPS (37c), consensus (74c) 08/08/22 Sutro Biopharma reports Q2 EPS (55c), consensus (46c) 08/15/22 Roivant Sciences reports Q1 EPS (48c) vs (13c) last year 06/28/22 Roivant Sciences reports Q4 EPS (39c), consensus (32c) 11/08/22 Avidity Biosciences reports Q3 EPS (82c), consensus (93c) 08/09/22 Avidity Biosciences reports Q2 EPS (92c), consensus (75c) 05/10/22 Avidity Biosciences reports Q1 EPS (71c), consensus (80c) MGTA Magenta Therapeutics 11/03/22 Magenta Therapeutics reports Q3 EPS (27c), consensus (30c) 08/04/22 Magenta Therapeutics reports Q2 EPS (29c), consensus (33c) 05/16/22 Magenta Therapeutics reports Q1 EPS (39c), consensus (31c) 08/17/22 Kamada reaffirms FY22 revenue view $125M-$135M 08/17/22 Kamada reports Q2 EPS (9c) vs 2c last year 05/17/22 Kamada reaffirms FY22 revenue view $125M-$135M 05/17/22 Kamada reports Q1 EPS (4c) vs 6c last year 10/18/22 Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B 10/18/22 Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75 10/18/22 Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07 10/18/22 Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48 10/26/22 Iqvia narrows FY22 adjusted EPS view to $10.10-$10.20 from $10.00-$10.20 10/26/22 Iqvia sees Q4 adjusted EPS $2.72-$2.82, consensus $2.81 10/26/22 Iqvia reports Q3 EPS $2.48, consensus $2.38 07/21/22 Iqvia raises FY22 adjusted EPS view to $10.00-$10.20 from $9.95-$10.25 GLUE Monte Rosa Therapeutics 08/11/22 Monte Rosa Therapeutics reports Q2 EPS (57c), consensus (54c) 05/11/22 Monte Rosa Therapeutics reports Q1 EPS (51c), consensus (52c) FULC Fulcrum Therapeutics 11/08/22 Fulcrum Therapeutics reports Q3 EPS (51c), consensus (61c) 08/11/22 Fulcrum Therapeutics reports Q2 EPS (83c), consensus (66c) 10/26/22 Notable companies reporting after market close 07/27/22 Community Health sees FY22 EPS ($2.55)-($1.65), consensus 96c 07/27/22 Community Health reports Q2 EPS ($2.52), consensus 4c 07/27/22 Notable companies reporting after market close 08/10/22 Cullinan reports Q2 EPS $3.77, consensus $5.42 05/16/22 Cullinan reports Q1 EPS (27c), consensus (61c) CCRN Cross Country Healthcare 11/02/22 Cross Country Healthcare sees Q4 adjusted EPS 85c-95c, consensus 74c 11/02/22 Cross Country Healthcare reports Q3 adjusted EPS $1.07, consensus 95c 09/14/22 Cross Country Healthcare sees Q4 revenue minimum $550M, consensus $519.55M 09/14/22 Cross Country Healthcare sees minimum 2023 revenue $2.2B, consensus $2.07B 08/05/22 Candel Therapeutics reports 2Q EPS (14c) vs ($1.46) last year 05/12/22 Candel Therapeutics reports Q1 EPS (3c), consensus (31c) $404.17 / +23.57 (+6.19%)
10/27/22 Bio-Rad sees FY22 non-GAAP currency-neutral revenue growth at high end of 1%-2% 10/27/22 Bio-Rad reports Q3 EPS $2.60, consensus $2.78 07/28/22 Bio-Rad sees FY22 currency-neutral revenue growth high end of 1%-2% 07/28/22 Bio-Rad reports Q2 adjusted EPS $3.38, consensus $2.80 11/07/22 Amwell sees clear visibility to achieving FY revenue at lower end of guidance 11/07/22 Amwell reports Q3 EPS (25c), consensus (26c) 08/04/22 Amwell backs FY22 revenue view of $275M-$285M, consensus $276.8M 08/04/22 Amwell reports Q2 EPS (25c), consensus (26c) 11/09/22 Absci reports Q3 EPS (30c), consensus (28c) 08/11/22 Absci reports Q2 EPS (32c), consensus (30c) 05/11/22 Absci reports Q1 EPS (33c), consensus (29c)
Conference/Events
31st Annual Healthcare…
31st Annual Healthcare Conference to be held in Rancho Palos Verdes, CA on November 7-10.
Show Hide Related Items >> <<
10/31/22 United Therapeutics reports preliminary analysis from EXPEDITE study 10/27/22 Liquidia announces POP panel denies UTC request for review of IPR decsion 10/11/22 United Therapeutics enrolls first patient in phase 3 TETON 2 study 09/21/22 United Therapeutics announces termination of PERFECT clinical study of Tyvaso TOI The Oncology Institute 10/11/22 The Oncology Institute appoints Phil Reger as CIO 10/06/22 The Oncology Institute expands into South Florida 09/29/22 The Oncology Institute enrolls first patients in Phase 3 trial of pirtobrutinib 09/12/22 The Oncology Institute becomes certified as a Patient Safety Organization 09/08/22 Tandem Diabetes CFO says 'goal is always to beat' guidance 09/08/22 Tandem Diabetes CEO saw 'positive shift,' start of 'momentum build' in August 08/18/22 Tandem Diabetes achieves milestone of 1M insulin boluses delivered using app 07/21/22 Tandem Diabetes acquires Capillary Biomedical, terms not disclosed 10/21/22 Tenet Healthcare falls -31.7% 10/21/22 Tenet Healthcare falls -29.4% 10/21/22 Tenet Healthcare falls -26.0% 10/20/22 Tenet Healthcare drops 17% to $45.00 after Q4 guidance misses estimates 11/02/22 Protagonist Therapeutics names Arturo Molina as Chief Medical Officer 10/24/22 Sutro Biopharma announces departure of Chief Medical Officer 08/08/22 Sutro Biopharma sees projected cash runway into 1H24 07/26/22 Sutro:1st patient dosed in study with Merck for cytokine derivative for cancer 06/28/22 Pfizer and Roivant Sciences unveil Priovant Therapeutics 05/24/22 Dermavant Sciences announces FDA approval of VTAMA cream, 1% 05/16/22 Aruvant announces oral presentation on ARU-1801 10/11/22 Avidity Biosciences announces Phase1/2 Explore 44 clinical trial 09/27/22 Avidity Biosciences drops 20% after FDA partial clinical hold on MARINA trial 09/27/22 Avidity: Partial clinical hold due to SAE reported in single participant 09/27/22 Avidity Biosciences announces FDA partial clinical hold on trial enrollment MGTA Magenta Therapeutics 11/03/22 Magenta Therapeutics to present MGTA-117 data at 2022 ASH meeting 11/03/22 Magenta Therapeutics expects cash to fund operations into Q2 of 2024 11/03/22 Magenta Therapeutics to present data at 2022 ASH meeting 08/17/22 Magenta Therapeutics appoints Vasconcelles to board of directors 11/07/22 Kamada provides update on progress in Phase 3 trial of inhaled AAT 10/19/22 Kamada awarded $22M extension of Canadian supply tender 07/15/22 Kamada announces resolution to the labor strike at facility in Israel 07/06/22 Kamada secures $11.4M international Varizig procurement agreement $173.86 / +0.895 (+0.52%)
11/07/22 Avalo sells economic rights to previously out-licensed assets for $5M 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 11/01/22 J&J: Abiomed acquisition has enterprise value of $16.6B 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 09/28/22 Iqvia Decentralized Clinical Trial program achieves independent GDPR validation 08/15/22 Third Point adds Disney, exits Intuit in Q2 08/08/22 GSK, IQVIA launch Vaccine Track platform 06/07/22 Iqvia appoints Mack as Chief Scientific Officer of RWS GLUE Monte Rosa Therapeutics 11/01/22 Monte Rosa announces first patient dosed in phase 1/2 trial of MRT-2359 09/06/22 Monte Rosa Therapeutics announces FDA cleared IND for MRT-2359 08/11/22 Monte Rosa Therapeutics sees cash funding operations into late 2024 05/11/22 Monte Rosa Therapeutics sees cash, equivalents funding operations into late 2024 FULC Fulcrum Therapeutics 11/07/22 Fulcrum appoints new Chief Medical and new Chief Scientific officers 10/20/22 Fulcrum Therapeutics reports resignation of president of R&D 10/12/22 Fulcrum Therapeutics to present data from OLE portion of Phase 2 ReDUX4 study 08/11/22 Fulcrum Therapeutics expects cash to fund operations into mid-2024 07/28/22 Community Health trading resumes 07/28/22 Community Health trading halted, volatility trading pause 07/22/22 Community Health rises 22.2% 07/22/22 Community Health rises 14.1% 11/02/22 Cullinan appoints Ryan to board of directors 10/25/22 Cullinan increases ownership stake in its MICA subsidiary 08/15/22 Cullinan announces Jacquelyn Sumer as chief legal officer 08/10/22 Cullinan expects cash to fund operations through 2026 CCRN Cross Country Healthcare 09/14/22 Cross Country Healthcare sees path to $3B in revenue, $300M in EBITDA 09/13/22 Cross Country Healthcare to acquire Mint Medical Physician Staffing, LP 08/16/22 Cross Country Healthcare board authorizes up to $100M share repurchase program 10/26/22 Candel Therapeutics partners with Penn to study novel viral immunotherapies 09/15/22 Candel Therapeutics receives orphan drug designation for CAN--2409 09/07/22 Candel Therapeutics appoints Jason Amello as CFO, Garrett Nichols as CMO 08/01/22 Candel Therapeutics appoints three new members to board of directors $380.66 / +2.525 (+0.67%)
10/10/22 Qiagen up 5%, Bio-Rad down 6% following WSJ report on talks to combine 08/03/22 Bio-Rad acquires Curiosity Diagnostics for total consideration of up to $170M 07/28/22 Bio-Rad increases stock buyback authorization by $200M 06/27/22 Bio-Rad publishes corporate sustainability report 09/14/22 Amwell appoints Matthew McAllister as Chief Product Officer 08/25/22 Teladoc, Amwell rise after Amazon says will shut down Amazon Care 06/14/22 Amwell falls -8.6% 06/08/22 Amwell appoints Nelson as Chief Medical Officer 11/02/22 Absci appoints Rabinovitsj to board of directors 10/04/22 Absci appoints Andreas Busch as Chief Innovation Officer 07/14/22 Absci hires Dettore as Chief People Officer, Gold as Chief Marketing Officer 07/07/22 Absci enters multi-program collaboration with biotech partner 08/12/22 JPMorgan Absci double downgraded to Underweight at JPMorgan on slower revenue ramp 08/12/22 JPMorgan Absci downgraded to Underweight from Overweight at JPMorgan 08/12/22 Cowen Absci upgraded to Outperform from Market Perform at Cowen 07/18/22 Truist Truist starts Absci at Buy on confluence of biotech, next-gen biologics 08/04/22 Citi Community Health price target lowered to $6 from $14 at Citi 07/29/22 Oppenheimer Community Health price target lowered to $6 from $16 at Oppenheimer 06/16/22 Loop Capital Loop starts Community Health at Hold amid labor challenges 06/16/22 Loop Capital Community Health initiated with a Hold at Loop Capital 10/27/22 Credit Suisse Iqvia price target lowered to $265 from $300 at Credit Suisse 10/27/22 Citi Iqvia price target lowered to $275 from $290 at Citi 10/27/22 Barclays Iqvia price target raised to $235 from $215 at Barclays 10/18/22 Deutsche Bank Iqvia price target lowered to $270 from $290 at Deutsche Bank 09/27/22 Chardan Avidity Biosciences price target lowered to $27 from $29 at Chardan 07/20/22 Chardan Avidity Biosciences initiated with a Buy at Chardan 07/11/22 Raymond James Avidity Biosciences initiated with a Strong Buy at Raymond James 10/27/22 JPMorgan Roivant Sciences initiated with an Overweight at JPMorgan 08/16/22 Citi Roivant Sciences price target raised to $10 from $9 at Citi 05/23/22 SVB Securities Roivant Sciences initiated with an Outperform at SVB Leerink 04/29/22 Cantor Fitzgerald Roivant Sciences initiated with an Overweight at Cantor Fitzgerald $173.86 / +0.895 (+0.52%)
11/02/22 Morgan Stanley Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/22 Deutsche Bank Abiomed downgraded to Hold from Buy at Deutsche Bank 11/01/22 Piper Sandler Abiomed downgraded to Neutral from Overweight at Piper Sandler 11/01/22 Cowen Cowen starts Legend Biotech with an Outperform on Carvykti potential MGTA Magenta Therapeutics 08/24/22 Goldman Sachs Magenta downgraded on limited clinical catalysts at Goldman Sachs 08/24/22 Goldman Sachs Magenta Therapeutics downgraded to Neutral from Buy at Goldman Sachs 04/18/22 Mizuho Magenta Therapeutics price target lowered to $8 from $17 at Mizuho 04/18/22 BTIG Magenta Therapeutics price target lowered to $6 from $10 at BTIG 08/23/22 Truist Sutro Biopharma price target lowered to $21 from $37 at Truist 08/18/22 Wells Fargo Sutro Biopharma assumed with an Overweight at Wells Fargo 06/28/22 Piper Sandler Sutro Biopharma price target raised to $16 from $14 at Piper Sandler 05/23/22 Piper Sandler Sutro Biopharma price target lowered to $14 from $29 at Piper Sandler 10/27/22 Raymond James Tenet Healthcare price target lowered to $80 from $135 at Raymond James 10/25/22 Citi Tenet Healthcare shares offer 'significant upside,' says Citi 10/24/22 Truist Tenet Healthcare price target lowered to $55 from $80 at Truist 10/24/22 Deutsche Bank Tenet Healthcare price target lowered to $48 from $90 at Deutsche Bank 11/03/22 Lake Street Tandem Diabetes price target lowered to $60 from $150 at Lake Street 11/03/22 Craig-Hallum Tandem Diabetes price target lowered to $80 from $105 at Craig-Hallum 11/03/22 Cowen Tandem Diabetes price target lowered to $61 from $107 at Cowen 11/03/22 Baird Tandem Diabetes price target lowered to $45 from $76 at Baird TOI The Oncology Institute 09/14/22 Guggenheim The Oncology Institute initiated with a Buy at Guggenheim 08/15/22 Jefferies The Oncology Institute initiated with a Buy at Jefferies 11/03/22 Wedbush United Therapeutics price target raised to $305 from $250 at Wedbush 11/03/22 Oppenheimer United Therapeutics price target raised to $375 from $325 at Oppenheimer 11/03/22 H.C. Wainwright United Therapeutics price target raised to $300 from $255 at H.C. Wainwright 10/11/22 Morgan Stanley United Therapeutics initiated with an Overweight at Morgan Stanley CCRN Cross Country Healthcare 11/07/22 Barrington Cross Country Healthcare price target raised to $45 from $41 at Barrington 10/05/22 Truist Cross Country Healthcare downgraded to Hold at Truist on valuation 10/05/22 Truist Cross Country Healthcare downgraded to Hold from Buy at Truist 09/15/22 Benchmark Cross Country Healthcare price target raised to $42 from $37 at Benchmark FULC Fulcrum Therapeutics 11/08/22 Piper Sandler Fulcrum Therapeutics price target lowered to $18 from $42 at Piper Sandler 10/20/22 Stifel Fulcrum Therapeutics price target lowered to $35 from $43 at Stifel 06/10/22 Piper Sandler Fulcrum should be bought on today's selloff, says Piper Sandler 06/10/22 H.C. Wainwright H.C. Wainwright says Fulcrum data 'raises multiple questions,' halves target 03/31/22 BMO Capital Candel Therapeutics price target lowered to $12 from $18 at BMO Capital 11/18/21 BMO Capital Candel Therapeutics initiated with an Outperform at BMO Capital $380.66 / +2.525 (+0.67%)
10/11/22 Jefferies Jefferies 'not surprised' by report of Bio-Rad talks to combine with Qiagen 08/24/22 Credit Suisse Bio-Rad initiated with an Outperform at Credit Suisse 07/08/22 Citi Bio-Rad price target lowered to $700 from $750 at Citi 05/02/22 Citi Bio-Rad price target lowered to $750 from $800 at Citi 09/07/22 Truist Amwell initiated with a Hold at Truist 09/07/22 Piper Sandler Amwell price target lowered to $5 from $6 at Piper Sandler 06/23/22 Piper Sandler Amwell price target raised to $6 from $5 at Piper Sandler 06/03/22 Morgan Stanley CVS deal a 'game-changer' for Amwell's Converge, says Morgan Stanley GLUE Monte Rosa Therapeutics 10/13/22 UBS Monte Rosa Therapeutics initiated with a Buy at UBS 08/15/22 Jefferies Monte Rosa Therapeutics initiated with a Buy at Jefferies 05/11/22 Piper Sandler Monte Rosa Therapeutics price target lowered to $21 from $40 at Piper Sandler 04/28/22 Credit Suisse Monte Rosa Therapeutics initiated with a Neutral at Credit Suisse 11/02/22 United Therapeutics reports Q3 EPS $4.91, consensus $3.89 08/03/22 United Therapeutics reports Q2 EPS $2.41, consensus $4.12 TOI The Oncology Institute 08/09/22 The Oncology Institute reports Q2 EPS (6c) vs. (5c) last year 11/02/22 Tandem Diabetes cuts FY22 revenue view to $800M-$805M, consensus $836.4M 11/02/22 Tandem Diabetes reports Q3 EPS (76c), consensus (5c) 08/03/22 Tandem Diabetes cuts FY22 revenue view to $835M-$845 from $850M-$865M 08/03/22 Tandem Diabetes reports Q2 EPS (24c), consensus 2c 10/20/22 Tenet narrows FY22 EPS view to $5.88-$6.42 from $5.80-$7, consensus $6.46 10/20/22 Tenet Healthcare sees Q4 adjusted EPS $1.00-$1.54, consensus $1.80 10/20/22 Tenet Healthcare reports Q3 adjusted EPS $1.44, consensus $1.24 10/20/22 Notable companies reporting after market close 11/08/22 Sutro Biopharma reports Q3 EPS (37c), consensus (74c) 08/08/22 Sutro Biopharma reports Q2 EPS (55c), consensus (46c) 05/09/22 Sutro Biopharma reports Q1 EPS (84c), consensus (76c) 08/15/22 Roivant Sciences reports Q1 EPS (48c) vs (13c) last year 06/28/22 Roivant Sciences reports Q4 EPS (39c), consensus (32c) 11/08/22 Avidity Biosciences reports Q3 EPS (82c), consensus (93c) 08/09/22 Avidity Biosciences reports Q2 EPS (92c), consensus (75c) 05/10/22 Avidity Biosciences reports Q1 EPS (71c), consensus (80c) MGTA Magenta Therapeutics 11/03/22 Magenta Therapeutics reports Q3 EPS (27c), consensus (30c) 08/04/22 Magenta Therapeutics reports Q2 EPS (29c), consensus (33c) 05/16/22 Magenta Therapeutics reports Q1 EPS (39c), consensus (31c) 08/17/22 Kamada reaffirms FY22 revenue view $125M-$135M 08/17/22 Kamada reports Q2 EPS (9c) vs 2c last year 05/17/22 Kamada reaffirms FY22 revenue view $125M-$135M 05/17/22 Kamada reports Q1 EPS (4c) vs 6c last year $173.86 / +0.895 (+0.52%)
10/18/22 Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B 10/18/22 Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75 10/18/22 Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07 10/18/22 Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48 10/26/22 Iqvia narrows FY22 adjusted EPS view to $10.10-$10.20 from $10.00-$10.20 10/26/22 Iqvia sees Q4 adjusted EPS $2.72-$2.82, consensus $2.81 10/26/22 Iqvia reports Q3 EPS $2.48, consensus $2.38 07/21/22 Iqvia raises FY22 adjusted EPS view to $10.00-$10.20 from $9.95-$10.25 GLUE Monte Rosa Therapeutics 08/11/22 Monte Rosa Therapeutics reports Q2 EPS (57c), consensus (54c) 05/11/22 Monte Rosa Therapeutics reports Q1 EPS (51c), consensus (52c) FULC Fulcrum Therapeutics 11/08/22 Fulcrum Therapeutics reports Q3 EPS (51c), consensus (61c) 08/11/22 Fulcrum Therapeutics reports Q2 EPS (83c), consensus (66c) 05/09/22 Fulcrum Therapeutics reports Q1 EPS (64c), consensus (63c) 10/26/22 Notable companies reporting after market close 07/27/22 Community Health sees FY22 EPS ($2.55)-($1.65), consensus 96c 07/27/22 Community Health reports Q2 EPS ($2.52), consensus 4c 07/27/22 Notable companies reporting after market close 08/10/22 Cullinan reports Q2 EPS $3.77, consensus $5.42 05/16/22 Cullinan reports Q1 EPS (27c), consensus (61c) CCRN Cross Country Healthcare 11/02/22 Cross Country Healthcare sees Q4 adjusted EPS 85c-95c, consensus 74c 11/02/22 Cross Country Healthcare reports Q3 adjusted EPS $1.07, consensus 95c 09/14/22 Cross Country Healthcare sees Q4 revenue minimum $550M, consensus $519.55M 09/14/22 Cross Country Healthcare sees minimum 2023 revenue $2.2B, consensus $2.07B 08/05/22 Candel Therapeutics reports 2Q EPS (14c) vs ($1.46) last year 05/12/22 Candel Therapeutics reports Q1 EPS (3c), consensus (31c) $380.66 / +2.525 (+0.67%)
10/27/22 Bio-Rad sees FY22 non-GAAP currency-neutral revenue growth at high end of 1%-2% 10/27/22 Bio-Rad reports Q3 EPS $2.60, consensus $2.78 07/28/22 Bio-Rad sees FY22 currency-neutral revenue growth high end of 1%-2% 07/28/22 Bio-Rad reports Q2 adjusted EPS $3.38, consensus $2.80 11/07/22 Amwell sees clear visibility to achieving FY revenue at lower end of guidance 11/07/22 Amwell reports Q3 EPS (25c), consensus (26c) 08/04/22 Amwell backs FY22 revenue view of $275M-$285M, consensus $276.8M 08/04/22 Amwell reports Q2 EPS (25c), consensus (26c) 08/11/22 Absci reports Q2 EPS (32c), consensus (30c) 05/11/22 Absci reports Q1 EPS (33c), consensus (29c)
Conference/Events
31st Annual Healthcare…
31st Annual Healthcare Conference to be held in Rancho Palos Verdes, CA on November 7-10.
Show Hide Related Items >> <<
$266.76 / +1.805 (+0.68%)
10/31/22 United Therapeutics reports preliminary analysis from EXPEDITE study 10/27/22 Liquidia announces POP panel denies UTC request for review of IPR decsion 10/11/22 United Therapeutics enrolls first patient in phase 3 TETON 2 study 09/21/22 United Therapeutics announces termination of PERFECT clinical study of Tyvaso TOI The Oncology Institute 10/11/22 The Oncology Institute appoints Phil Reger as CIO 10/06/22 The Oncology Institute expands into South Florida 09/29/22 The Oncology Institute enrolls first patients in Phase 3 trial of pirtobrutinib 09/12/22 The Oncology Institute becomes certified as a Patient Safety Organization 09/08/22 Tandem Diabetes CFO says 'goal is always to beat' guidance 09/08/22 Tandem Diabetes CEO saw 'positive shift,' start of 'momentum build' in August 08/18/22 Tandem Diabetes achieves milestone of 1M insulin boluses delivered using app 07/21/22 Tandem Diabetes acquires Capillary Biomedical, terms not disclosed 10/21/22 Tenet Healthcare falls -31.7% 10/21/22 Tenet Healthcare falls -29.4% 10/21/22 Tenet Healthcare falls -26.0% 10/20/22 Tenet Healthcare drops 17% to $45.00 after Q4 guidance misses estimates 11/02/22 Protagonist Therapeutics names Arturo Molina as Chief Medical Officer 10/24/22 Sutro Biopharma announces departure of Chief Medical Officer 08/08/22 Sutro Biopharma sees projected cash runway into 1H24 07/26/22 Sutro:1st patient dosed in study with Merck for cytokine derivative for cancer 06/28/22 Pfizer and Roivant Sciences unveil Priovant Therapeutics 05/24/22 Dermavant Sciences announces FDA approval of VTAMA cream, 1% 05/16/22 Aruvant announces oral presentation on ARU-1801 10/11/22 Avidity Biosciences announces Phase1/2 Explore 44 clinical trial 09/27/22 Avidity Biosciences drops 20% after FDA partial clinical hold on MARINA trial 09/27/22 Avidity: Partial clinical hold due to SAE reported in single participant 09/27/22 Avidity Biosciences announces FDA partial clinical hold on trial enrollment MGTA Magenta Therapeutics 11/03/22 Magenta Therapeutics to present MGTA-117 data at 2022 ASH meeting 11/03/22 Magenta Therapeutics expects cash to fund operations into Q2 of 2024 11/03/22 Magenta Therapeutics to present data at 2022 ASH meeting 08/17/22 Magenta Therapeutics appoints Vasconcelles to board of directors 11/07/22 Kamada provides update on progress in Phase 3 trial of inhaled AAT 10/19/22 Kamada awarded $22M extension of Canadian supply tender 07/15/22 Kamada announces resolution to the labor strike at facility in Israel 07/06/22 Kamada secures $11.4M international Varizig procurement agreement 11/07/22 Avalo sells economic rights to previously out-licensed assets for $5M 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 11/01/22 J&J: Abiomed acquisition has enterprise value of $16.6B 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 09/28/22 Iqvia Decentralized Clinical Trial program achieves independent GDPR validation 08/15/22 Third Point adds Disney, exits Intuit in Q2 08/08/22 GSK, IQVIA launch Vaccine Track platform 06/07/22 Iqvia appoints Mack as Chief Scientific Officer of RWS GLUE Monte Rosa Therapeutics 11/01/22 Monte Rosa announces first patient dosed in phase 1/2 trial of MRT-2359 09/06/22 Monte Rosa Therapeutics announces FDA cleared IND for MRT-2359 08/11/22 Monte Rosa Therapeutics sees cash funding operations into late 2024 05/11/22 Monte Rosa Therapeutics sees cash, equivalents funding operations into late 2024 FULC Fulcrum Therapeutics 11/07/22 Fulcrum appoints new Chief Medical and new Chief Scientific officers 10/20/22 Fulcrum Therapeutics reports resignation of president of R&D 10/12/22 Fulcrum Therapeutics to present data from OLE portion of Phase 2 ReDUX4 study 08/11/22 Fulcrum Therapeutics expects cash to fund operations into mid-2024 07/28/22 Community Health trading resumes 07/28/22 Community Health trading halted, volatility trading pause 07/22/22 Community Health rises 22.2% 07/22/22 Community Health rises 14.1% 11/02/22 Cullinan appoints Ryan to board of directors 10/25/22 Cullinan increases ownership stake in its MICA subsidiary 08/15/22 Cullinan announces Jacquelyn Sumer as chief legal officer 08/10/22 Cullinan expects cash to fund operations through 2026 CCRN Cross Country Healthcare 09/14/22 Cross Country Healthcare sees path to $3B in revenue, $300M in EBITDA 09/13/22 Cross Country Healthcare to acquire Mint Medical Physician Staffing, LP 08/16/22 Cross Country Healthcare board authorizes up to $100M share repurchase program 10/26/22 Candel Therapeutics partners with Penn to study novel viral immunotherapies 09/15/22 Candel Therapeutics receives orphan drug designation for CAN--2409 09/07/22 Candel Therapeutics appoints Jason Amello as CFO, Garrett Nichols as CMO 08/01/22 Candel Therapeutics appoints three new members to board of directors 10/10/22 Qiagen up 5%, Bio-Rad down 6% following WSJ report on talks to combine 08/03/22 Bio-Rad acquires Curiosity Diagnostics for total consideration of up to $170M 07/28/22 Bio-Rad increases stock buyback authorization by $200M 06/27/22 Bio-Rad publishes corporate sustainability report 09/14/22 Amwell appoints Matthew McAllister as Chief Product Officer 08/25/22 Teladoc, Amwell rise after Amazon says will shut down Amazon Care 06/14/22 Amwell falls -8.6% 06/08/22 Amwell appoints Nelson as Chief Medical Officer 11/02/22 Absci appoints Rabinovitsj to board of directors 10/04/22 Absci appoints Andreas Busch as Chief Innovation Officer 07/14/22 Absci hires Dettore as Chief People Officer, Gold as Chief Marketing Officer 07/07/22 Absci enters multi-program collaboration with biotech partner 08/12/22 JPMorgan Absci double downgraded to Underweight at JPMorgan on slower revenue ramp 08/12/22 JPMorgan Absci downgraded to Underweight from Overweight at JPMorgan 08/12/22 Cowen Absci upgraded to Outperform from Market Perform at Cowen 07/18/22 Truist Truist starts Absci at Buy on confluence of biotech, next-gen biologics 08/04/22 Citi Community Health price target lowered to $6 from $14 at Citi 07/29/22 Oppenheimer Community Health price target lowered to $6 from $16 at Oppenheimer 06/16/22 Loop Capital Loop starts Community Health at Hold amid labor challenges 06/16/22 Loop Capital Community Health initiated with a Hold at Loop Capital 10/27/22 Credit Suisse Iqvia price target lowered to $265 from $300 at Credit Suisse 10/27/22 Citi Iqvia price target lowered to $275 from $290 at Citi 10/27/22 Barclays Iqvia price target raised to $235 from $215 at Barclays 10/18/22 Deutsche Bank Iqvia price target lowered to $270 from $290 at Deutsche Bank 09/27/22 Chardan Avidity Biosciences price target lowered to $27 from $29 at Chardan 07/20/22 Chardan Avidity Biosciences initiated with a Buy at Chardan 07/11/22 Raymond James Avidity Biosciences initiated with a Strong Buy at Raymond James 10/27/22 JPMorgan Roivant Sciences initiated with an Overweight at JPMorgan 08/16/22 Citi Roivant Sciences price target raised to $10 from $9 at Citi 05/23/22 SVB Securities Roivant Sciences initiated with an Outperform at SVB Leerink 04/29/22 Cantor Fitzgerald Roivant Sciences initiated with an Overweight at Cantor Fitzgerald 11/02/22 Morgan Stanley Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/22 Deutsche Bank Abiomed downgraded to Hold from Buy at Deutsche Bank 11/01/22 Piper Sandler Abiomed downgraded to Neutral from Overweight at Piper Sandler 11/01/22 Cowen Cowen starts Legend Biotech with an Outperform on Carvykti potential MGTA Magenta Therapeutics 08/24/22 Goldman Sachs Magenta downgraded on limited clinical catalysts at Goldman Sachs 08/24/22 Goldman Sachs Magenta Therapeutics downgraded to Neutral from Buy at Goldman Sachs 04/18/22 Mizuho Magenta Therapeutics price target lowered to $8 from $17 at Mizuho 04/18/22 BTIG Magenta Therapeutics price target lowered to $6 from $10 at BTIG 08/23/22 Truist Sutro Biopharma price target lowered to $21 from $37 at Truist 08/18/22 Wells Fargo Sutro Biopharma assumed with an Overweight at Wells Fargo 06/28/22 Piper Sandler Sutro Biopharma price target raised to $16 from $14 at Piper Sandler 05/23/22 Piper Sandler Sutro Biopharma price target lowered to $14 from $29 at Piper Sandler 10/27/22 Raymond James Tenet Healthcare price target lowered to $80 from $135 at Raymond James 10/25/22 Citi Tenet Healthcare shares offer 'significant upside,' says Citi 10/24/22 Truist Tenet Healthcare price target lowered to $55 from $80 at Truist 10/24/22 Deutsche Bank Tenet Healthcare price target lowered to $48 from $90 at Deutsche Bank 11/03/22 Lake Street Tandem Diabetes price target lowered to $60 from $150 at Lake Street 11/03/22 Craig-Hallum Tandem Diabetes price target lowered to $80 from $105 at Craig-Hallum 11/03/22 Cowen Tandem Diabetes price target lowered to $61 from $107 at Cowen 11/03/22 Baird Tandem Diabetes price target lowered to $45 from $76 at Baird TOI The Oncology Institute 09/14/22 Guggenheim The Oncology Institute initiated with a Buy at Guggenheim 08/15/22 Jefferies The Oncology Institute initiated with a Buy at Jefferies $266.76 / +1.805 (+0.68%)
11/03/22 Wedbush United Therapeutics price target raised to $305 from $250 at Wedbush 11/03/22 Oppenheimer United Therapeutics price target raised to $375 from $325 at Oppenheimer 11/03/22 H.C. Wainwright United Therapeutics price target raised to $300 from $255 at H.C. Wainwright 10/11/22 Morgan Stanley United Therapeutics initiated with an Overweight at Morgan Stanley CCRN Cross Country Healthcare 11/07/22 Barrington Cross Country Healthcare price target raised to $45 from $41 at Barrington 10/05/22 Truist Cross Country Healthcare downgraded to Hold at Truist on valuation 10/05/22 Truist Cross Country Healthcare downgraded to Hold from Buy at Truist 09/15/22 Benchmark Cross Country Healthcare price target raised to $42 from $37 at Benchmark FULC Fulcrum Therapeutics 10/20/22 Stifel Fulcrum Therapeutics price target lowered to $35 from $43 at Stifel 06/10/22 Piper Sandler Fulcrum should be bought on today's selloff, says Piper Sandler 06/10/22 H.C. Wainwright H.C. Wainwright says Fulcrum data 'raises multiple questions,' halves target 06/10/22 Oppenheimer FTX-6058 benefits outweigh unresolved answers, says Oppenheimer 03/31/22 BMO Capital Candel Therapeutics price target lowered to $12 from $18 at BMO Capital 11/18/21 BMO Capital Candel Therapeutics initiated with an Outperform at BMO Capital 10/11/22 Jefferies Jefferies 'not surprised' by report of Bio-Rad talks to combine with Qiagen 08/24/22 Credit Suisse Bio-Rad initiated with an Outperform at Credit Suisse 07/08/22 Citi Bio-Rad price target lowered to $700 from $750 at Citi 05/02/22 Citi Bio-Rad price target lowered to $750 from $800 at Citi 09/07/22 Truist Amwell initiated with a Hold at Truist 09/07/22 Piper Sandler Amwell price target lowered to $5 from $6 at Piper Sandler 06/23/22 Piper Sandler Amwell price target raised to $6 from $5 at Piper Sandler 06/03/22 Morgan Stanley CVS deal a 'game-changer' for Amwell's Converge, says Morgan Stanley GLUE Monte Rosa Therapeutics 10/13/22 UBS Monte Rosa Therapeutics initiated with a Buy at UBS 08/15/22 Jefferies Monte Rosa Therapeutics initiated with a Buy at Jefferies 05/11/22 Piper Sandler Monte Rosa Therapeutics price target lowered to $21 from $40 at Piper Sandler 04/28/22 Credit Suisse Monte Rosa Therapeutics initiated with a Neutral at Credit Suisse $266.76 / +1.805 (+0.68%)
11/02/22 United Therapeutics reports Q3 EPS $4.91, consensus $3.89 08/03/22 United Therapeutics reports Q2 EPS $2.41, consensus $4.12 TOI The Oncology Institute 08/09/22 The Oncology Institute reports Q2 EPS (6c) vs. (5c) last year 11/02/22 Tandem Diabetes cuts FY22 revenue view to $800M-$805M, consensus $836.4M 11/02/22 Tandem Diabetes reports Q3 EPS (76c), consensus (5c) 08/03/22 Tandem Diabetes cuts FY22 revenue view to $835M-$845 from $850M-$865M 08/03/22 Tandem Diabetes reports Q2 EPS (24c), consensus 2c 10/20/22 Tenet narrows FY22 EPS view to $5.88-$6.42 from $5.80-$7, consensus $6.46 10/20/22 Tenet Healthcare sees Q4 adjusted EPS $1.00-$1.54, consensus $1.80 10/20/22 Tenet Healthcare reports Q3 adjusted EPS $1.44, consensus $1.24 10/20/22 Notable companies reporting after market close 08/08/22 Sutro Biopharma reports Q2 EPS (55c), consensus (46c) 05/09/22 Sutro Biopharma reports Q1 EPS (84c), consensus (76c) 08/15/22 Roivant Sciences reports Q1 EPS (48c) vs (13c) last year 06/28/22 Roivant Sciences reports Q4 EPS (39c), consensus (32c) 08/09/22 Avidity Biosciences reports Q2 EPS (92c), consensus (75c) 05/10/22 Avidity Biosciences reports Q1 EPS (71c), consensus (80c) MGTA Magenta Therapeutics 11/03/22 Magenta Therapeutics reports Q3 EPS (27c), consensus (30c) 08/04/22 Magenta Therapeutics reports Q2 EPS (29c), consensus (33c) 05/16/22 Magenta Therapeutics reports Q1 EPS (39c), consensus (31c) 08/17/22 Kamada reaffirms FY22 revenue view $125M-$135M 08/17/22 Kamada reports Q2 EPS (9c) vs 2c last year 05/17/22 Kamada reaffirms FY22 revenue view $125M-$135M 05/17/22 Kamada reports Q1 EPS (4c) vs 6c last year 10/18/22 Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B 10/18/22 Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75 10/18/22 Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07 10/18/22 Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48 10/26/22 Iqvia narrows FY22 adjusted EPS view to $10.10-$10.20 from $10.00-$10.20 10/26/22 Iqvia sees Q4 adjusted EPS $2.72-$2.82, consensus $2.81 10/26/22 Iqvia reports Q3 EPS $2.48, consensus $2.38 07/21/22 Iqvia raises FY22 adjusted EPS view to $10.00-$10.20 from $9.95-$10.25 GLUE Monte Rosa Therapeutics 08/11/22 Monte Rosa Therapeutics reports Q2 EPS (57c), consensus (54c) 05/11/22 Monte Rosa Therapeutics reports Q1 EPS (51c), consensus (52c) FULC Fulcrum Therapeutics 08/11/22 Fulcrum Therapeutics reports Q2 EPS (83c), consensus (66c) 05/09/22 Fulcrum Therapeutics reports Q1 EPS (64c), consensus (63c) 10/26/22 Notable companies reporting after market close 07/27/22 Community Health sees FY22 EPS ($2.55)-($1.65), consensus 96c 07/27/22 Community Health reports Q2 EPS ($2.52), consensus 4c 07/27/22 Notable companies reporting after market close 08/10/22 Cullinan reports Q2 EPS $3.77, consensus $5.42 05/16/22 Cullinan reports Q1 EPS (27c), consensus (61c) CCRN Cross Country Healthcare 11/02/22 Cross Country Healthcare sees Q4 adjusted EPS 85c-95c, consensus 74c 11/02/22 Cross Country Healthcare reports Q3 adjusted EPS $1.07, consensus 95c 09/14/22 Cross Country Healthcare sees Q4 revenue minimum $550M, consensus $519.55M 09/14/22 Cross Country Healthcare sees minimum 2023 revenue $2.2B, consensus $2.07B 08/05/22 Candel Therapeutics reports 2Q EPS (14c) vs ($1.46) last year 05/12/22 Candel Therapeutics reports Q1 EPS (3c), consensus (31c) 10/27/22 Bio-Rad sees FY22 non-GAAP currency-neutral revenue growth at high end of 1%-2% 10/27/22 Bio-Rad reports Q3 EPS $2.60, consensus $2.78 07/28/22 Bio-Rad sees FY22 currency-neutral revenue growth high end of 1%-2% 07/28/22 Bio-Rad reports Q2 adjusted EPS $3.38, consensus $2.80 11/07/22 Amwell sees clear visibility to achieving FY revenue at lower end of guidance 11/07/22 Amwell reports Q3 EPS (25c), consensus (26c) 08/04/22 Amwell backs FY22 revenue view of $275M-$285M, consensus $276.8M 08/04/22 Amwell reports Q2 EPS (25c), consensus (26c) 08/11/22 Absci reports Q2 EPS (32c), consensus (30c) 05/11/22 Absci reports Q1 EPS (33c), consensus (29c)
Conference/Events
31st Annual Healthcare…
31st Annual Healthcare Conference to be held in Rancho Palos Verdes, CA on November 7-10.
Show Hide Related Items >> <<
$266.76 / +1.805 (+0.68%)
10/31/22 United Therapeutics reports preliminary analysis from EXPEDITE study 10/27/22 Liquidia announces POP panel denies UTC request for review of IPR decsion 10/11/22 United Therapeutics enrolls first patient in phase 3 TETON 2 study 09/21/22 United Therapeutics announces termination of PERFECT clinical study of Tyvaso TOI The Oncology Institute 10/11/22 The Oncology Institute appoints Phil Reger as CIO 10/06/22 The Oncology Institute expands into South Florida 09/29/22 The Oncology Institute enrolls first patients in Phase 3 trial of pirtobrutinib 09/12/22 The Oncology Institute becomes certified as a Patient Safety Organization 09/08/22 Tandem Diabetes CFO says 'goal is always to beat' guidance 09/08/22 Tandem Diabetes CEO saw 'positive shift,' start of 'momentum build' in August 08/18/22 Tandem Diabetes achieves milestone of 1M insulin boluses delivered using app 07/21/22 Tandem Diabetes acquires Capillary Biomedical, terms not disclosed 10/21/22 Tenet Healthcare falls -31.7% 10/21/22 Tenet Healthcare falls -29.4% 10/21/22 Tenet Healthcare falls -26.0% 10/20/22 Tenet Healthcare drops 17% to $45.00 after Q4 guidance misses estimates 11/02/22 Protagonist Therapeutics names Arturo Molina as Chief Medical Officer 10/24/22 Sutro Biopharma announces departure of Chief Medical Officer 08/08/22 Sutro Biopharma sees projected cash runway into 1H24 07/26/22 Sutro:1st patient dosed in study with Merck for cytokine derivative for cancer 06/28/22 Pfizer and Roivant Sciences unveil Priovant Therapeutics 05/24/22 Dermavant Sciences announces FDA approval of VTAMA cream, 1% 05/16/22 Aruvant announces oral presentation on ARU-1801 10/11/22 Avidity Biosciences announces Phase1/2 Explore 44 clinical trial 09/27/22 Avidity Biosciences drops 20% after FDA partial clinical hold on MARINA trial 09/27/22 Avidity: Partial clinical hold due to SAE reported in single participant 09/27/22 Avidity Biosciences announces FDA partial clinical hold on trial enrollment MGTA Magenta Therapeutics 11/03/22 Magenta Therapeutics to present MGTA-117 data at 2022 ASH meeting 11/03/22 Magenta Therapeutics expects cash to fund operations into Q2 of 2024 11/03/22 Magenta Therapeutics to present data at 2022 ASH meeting 08/17/22 Magenta Therapeutics appoints Vasconcelles to board of directors 11/07/22 Kamada provides update on progress in Phase 3 trial of inhaled AAT 10/19/22 Kamada awarded $22M extension of Canadian supply tender 07/15/22 Kamada announces resolution to the labor strike at facility in Israel 07/06/22 Kamada secures $11.4M international Varizig procurement agreement 11/07/22 Avalo sells economic rights to previously out-licensed assets for $5M 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 11/01/22 J&J: Abiomed acquisition has enterprise value of $16.6B 11/01/22 Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash 09/28/22 Iqvia Decentralized Clinical Trial program achieves independent GDPR validation 08/15/22 Third Point adds Disney, exits Intuit in Q2 08/08/22 GSK, IQVIA launch Vaccine Track platform 06/07/22 Iqvia appoints Mack as Chief Scientific Officer of RWS GLUE Monte Rosa Therapeutics 11/01/22 Monte Rosa announces first patient dosed in phase 1/2 trial of MRT-2359 09/06/22 Monte Rosa Therapeutics announces FDA cleared IND for MRT-2359 08/11/22 Monte Rosa Therapeutics sees cash funding operations into late 2024 05/11/22 Monte Rosa Therapeutics sees cash, equivalents funding operations into late 2024 FULC Fulcrum Therapeutics 11/07/22 Fulcrum appoints new Chief Medical and new Chief Scientific officers 10/20/22 Fulcrum Therapeutics reports resignation of president of R&D 10/12/22 Fulcrum Therapeutics to present data from OLE portion of Phase 2 ReDUX4 study 08/11/22 Fulcrum Therapeutics expects cash to fund operations into mid-2024 07/28/22 Community Health trading resumes 07/28/22 Community Health trading halted, volatility trading pause 07/22/22 Community Health rises 22.2% 07/22/22 Community Health rises 14.1% 11/02/22 Cullinan appoints Ryan to board of directors 10/25/22 Cullinan increases ownership stake in its MICA subsidiary 08/15/22 Cullinan announces Jacquelyn Sumer as chief legal officer 08/10/22 Cullinan expects cash to fund operations through 2026 CCRN Cross Country Healthcare 09/14/22 Cross Country Healthcare sees path to $3B in revenue, $300M in EBITDA 09/13/22 Cross Country Healthcare to acquire Mint Medical Physician Staffing, LP 08/16/22 Cross Country Healthcare board authorizes up to $100M share repurchase program 10/26/22 Candel Therapeutics partners with Penn to study novel viral immunotherapies 09/15/22 Candel Therapeutics receives orphan drug designation for CAN--2409 09/07/22 Candel Therapeutics appoints Jason Amello as CFO, Garrett Nichols as CMO 08/01/22 Candel Therapeutics appoints three new members to board of directors 10/10/22 Qiagen up 5%, Bio-Rad down 6% following WSJ report on talks to combine 08/03/22 Bio-Rad acquires Curiosity Diagnostics for total consideration of up to $170M 07/28/22 Bio-Rad increases stock buyback authorization by $200M 06/27/22 Bio-Rad publishes corporate sustainability report 09/14/22 Amwell appoints Matthew McAllister as Chief Product Officer 08/25/22 Teladoc, Amwell rise after Amazon says will shut down Amazon Care 06/14/22 Amwell falls -8.6% 06/08/22 Amwell appoints Nelson as Chief Medical Officer 11/02/22 Absci appoints Rabinovitsj to board of directors 10/04/22 Absci appoints Andreas Busch as Chief Innovation Officer 07/14/22 Absci hires Dettore as Chief People Officer, Gold as Chief Marketing Officer 07/07/22 Absci enters multi-program collaboration with biotech partner 08/12/22 JPMorgan Absci double downgraded to Underweight at JPMorgan on slower revenue ramp 08/12/22 JPMorgan Absci downgraded to Underweight from Overweight at JPMorgan 08/12/22 Cowen Absci upgraded to Outperform from Market Perform at Cowen 07/18/22 Truist Truist starts Absci at Buy on confluence of biotech, next-gen biologics 08/04/22 Citi Community Health price target lowered to $6 from $14 at Citi 07/29/22 Oppenheimer Community Health price target lowered to $6 from $16 at Oppenheimer 06/16/22 Loop Capital Loop starts Community Health at Hold amid labor challenges 06/16/22 Loop Capital Community Health initiated with a Hold at Loop Capital 10/27/22 Credit Suisse Iqvia price target lowered to $265 from $300 at Credit Suisse 10/27/22 Citi Iqvia price target lowered to $275 from $290 at Citi 10/27/22 Barclays Iqvia price target raised to $235 from $215 at Barclays 10/18/22 Deutsche Bank Iqvia price target lowered to $270 from $290 at Deutsche Bank 09/27/22 Chardan Avidity Biosciences price target lowered to $27 from $29 at Chardan 07/20/22 Chardan Avidity Biosciences initiated with a Buy at Chardan 07/11/22 Raymond James Avidity Biosciences initiated with a Strong Buy at Raymond James 10/27/22 JPMorgan Roivant Sciences initiated with an Overweight at JPMorgan 08/16/22 Citi Roivant Sciences price target raised to $10 from $9 at Citi 05/23/22 SVB Securities Roivant Sciences initiated with an Outperform at SVB Leerink 04/29/22 Cantor Fitzgerald Roivant Sciences initiated with an Overweight at Cantor Fitzgerald 11/02/22 Morgan Stanley Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/22 Deutsche Bank Abiomed downgraded to Hold from Buy at Deutsche Bank 11/01/22 Piper Sandler Abiomed downgraded to Neutral from Overweight at Piper Sandler 11/01/22 Cowen Cowen starts Legend Biotech with an Outperform on Carvykti potential MGTA Magenta Therapeutics 08/24/22 Goldman Sachs Magenta downgraded on limited clinical catalysts at Goldman Sachs 08/24/22 Goldman Sachs Magenta Therapeutics downgraded to Neutral from Buy at Goldman Sachs 04/18/22 Mizuho Magenta Therapeutics price target lowered to $8 from $17 at Mizuho 04/18/22 BTIG Magenta Therapeutics price target lowered to $6 from $10 at BTIG 08/23/22 Truist Sutro Biopharma price target lowered to $21 from $37 at Truist 08/18/22 Wells Fargo Sutro Biopharma assumed with an Overweight at Wells Fargo 06/28/22 Piper Sandler Sutro Biopharma price target raised to $16 from $14 at Piper Sandler 05/23/22 Piper Sandler Sutro Biopharma price target lowered to $14 from $29 at Piper Sandler 10/27/22 Raymond James Tenet Healthcare price target lowered to $80 from $135 at Raymond James 10/25/22 Citi Tenet Healthcare shares offer 'significant upside,' says Citi 10/24/22 Truist Tenet Healthcare price target lowered to $55 from $80 at Truist 10/24/22 Deutsche Bank Tenet Healthcare price target lowered to $48 from $90 at Deutsche Bank 11/03/22 Lake Street Tandem Diabetes price target lowered to $60 from $150 at Lake Street 11/03/22 Craig-Hallum Tandem Diabetes price target lowered to $80 from $105 at Craig-Hallum 11/03/22 Cowen Tandem Diabetes price target lowered to $61 from $107 at Cowen 11/03/22 Baird Tandem Diabetes price target lowered to $45 from $76 at Baird TOI The Oncology Institute 09/14/22 Guggenheim The Oncology Institute initiated with a Buy at Guggenheim 08/15/22 Jefferies The Oncology Institute initiated with a Buy at Jefferies $266.76 / +1.805 (+0.68%)
11/03/22 Wedbush United Therapeutics price target raised to $305 from $250 at Wedbush 11/03/22 Oppenheimer United Therapeutics price target raised to $375 from $325 at Oppenheimer 11/03/22 H.C. Wainwright United Therapeutics price target raised to $300 from $255 at H.C. Wainwright 10/11/22 Morgan Stanley United Therapeutics initiated with an Overweight at Morgan Stanley CCRN Cross Country Healthcare 11/07/22 Barrington Cross Country Healthcare price target raised to $45 from $41 at Barrington 10/05/22 Truist Cross Country Healthcare downgraded to Hold at Truist on valuation 10/05/22 Truist Cross Country Healthcare downgraded to Hold from Buy at Truist 09/15/22 Benchmark Cross Country Healthcare price target raised to $42 from $37 at Benchmark FULC Fulcrum Therapeutics 10/20/22 Stifel Fulcrum Therapeutics price target lowered to $35 from $43 at Stifel 06/10/22 Piper Sandler Fulcrum should be bought on today's selloff, says Piper Sandler 06/10/22 H.C. Wainwright H.C. Wainwright says Fulcrum data 'raises multiple questions,' halves target 06/10/22 Oppenheimer FTX-6058 benefits outweigh unresolved answers, says Oppenheimer 03/31/22 BMO Capital Candel Therapeutics price target lowered to $12 from $18 at BMO Capital 11/18/21 BMO Capital Candel Therapeutics initiated with an Outperform at BMO Capital 10/11/22 Jefferies Jefferies 'not surprised' by report of Bio-Rad talks to combine with Qiagen 08/24/22 Credit Suisse Bio-Rad initiated with an Outperform at Credit Suisse 07/08/22 Citi Bio-Rad price target lowered to $700 from $750 at Citi 05/02/22 Citi Bio-Rad price target lowered to $750 from $800 at Citi 09/07/22 Truist Amwell initiated with a Hold at Truist 09/07/22 Piper Sandler Amwell price target lowered to $5 from $6 at Piper Sandler 06/23/22 Piper Sandler Amwell price target raised to $6 from $5 at Piper Sandler 06/03/22 Morgan Stanley CVS deal a 'game-changer' for Amwell's Converge, says Morgan Stanley GLUE Monte Rosa Therapeutics 10/13/22 UBS Monte Rosa Therapeutics initiated with a Buy at UBS 08/15/22 Jefferies Monte Rosa Therapeutics initiated with a Buy at Jefferies 05/11/22 Piper Sandler Monte Rosa Therapeutics price target lowered to $21 from $40 at Piper Sandler 04/28/22 Credit Suisse Monte Rosa Therapeutics initiated with a Neutral at Credit Suisse $266.76 / +1.805 (+0.68%)
11/02/22 United Therapeutics reports Q3 EPS $4.91, consensus $3.89 08/03/22 United Therapeutics reports Q2 EPS $2.41, consensus $4.12 TOI The Oncology Institute 08/09/22 The Oncology Institute reports Q2 EPS (6c) vs. (5c) last year 11/02/22 Tandem Diabetes cuts FY22 revenue view to $800M-$805M, consensus $836.4M 11/02/22 Tandem Diabetes reports Q3 EPS (76c), consensus (5c) 08/03/22 Tandem Diabetes cuts FY22 revenue view to $835M-$845 from $850M-$865M 08/03/22 Tandem Diabetes reports Q2 EPS (24c), consensus 2c 10/20/22 Tenet narrows FY22 EPS view to $5.88-$6.42 from $5.80-$7, consensus $6.46 10/20/22 Tenet Healthcare sees Q4 adjusted EPS $1.00-$1.54, consensus $1.80 10/20/22 Tenet Healthcare reports Q3 adjusted EPS $1.44, consensus $1.24 10/20/22 Notable companies reporting after market close 08/08/22 Sutro Biopharma reports Q2 EPS (55c), consensus (46c) 05/09/22 Sutro Biopharma reports Q1 EPS (84c), consensus (76c) 08/15/22 Roivant Sciences reports Q1 EPS (48c) vs (13c) last year 06/28/22 Roivant Sciences reports Q4 EPS (39c), consensus (32c) 08/09/22 Avidity Biosciences reports Q2 EPS (92c), consensus (75c) 05/10/22 Avidity Biosciences reports Q1 EPS (71c), consensus (80c) MGTA Magenta Therapeutics 11/03/22 Magenta Therapeutics reports Q3 EPS (27c), consensus (30c) 08/04/22 Magenta Therapeutics reports Q2 EPS (29c), consensus (33c) 05/16/22 Magenta Therapeutics reports Q1 EPS (39c), consensus (31c) 08/17/22 Kamada reaffirms FY22 revenue view $125M-$135M 08/17/22 Kamada reports Q2 EPS (9c) vs 2c last year 05/17/22 Kamada reaffirms FY22 revenue view $125M-$135M 05/17/22 Kamada reports Q1 EPS (4c) vs 6c last year 10/18/22 Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B 10/18/22 Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75 10/18/22 Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07 10/18/22 Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48 10/26/22 Iqvia narrows FY22 adjusted EPS view to $10.10-$10.20 from $10.00-$10.20 10/26/22 Iqvia sees Q4 adjusted EPS $2.72-$2.82, consensus $2.81 10/26/22 Iqvia reports Q3 EPS $2.48, consensus $2.38 07/21/22 Iqvia raises FY22 adjusted EPS view to $10.00-$10.20 from $9.95-$10.25 GLUE Monte Rosa Therapeutics 08/11/22 Monte Rosa Therapeutics reports Q2 EPS (57c), consensus (54c) 05/11/22 Monte Rosa Therapeutics reports Q1 EPS (51c), consensus (52c) FULC Fulcrum Therapeutics 08/11/22 Fulcrum Therapeutics reports Q2 EPS (83c), consensus (66c) 05/09/22 Fulcrum Therapeutics reports Q1 EPS (64c), consensus (63c) 10/26/22 Notable companies reporting after market close 07/27/22 Community Health sees FY22 EPS ($2.55)-($1.65), consensus 96c 07/27/22 Community Health reports Q2 EPS ($2.52), consensus 4c 07/27/22 Notable companies reporting after market close 08/10/22 Cullinan reports Q2 EPS $3.77, consensus $5.42 05/16/22 Cullinan reports Q1 EPS (27c), consensus (61c) CCRN Cross Country Healthcare 11/02/22 Cross Country Healthcare sees Q4 adjusted EPS 85c-95c, consensus 74c 11/02/22 Cross Country Healthcare reports Q3 adjusted EPS $1.07, consensus 95c 09/14/22 Cross Country Healthcare sees Q4 revenue minimum $550M, consensus $519.55M 09/14/22 Cross Country Healthcare sees minimum 2023 revenue $2.2B, consensus $2.07B 08/05/22 Candel Therapeutics reports 2Q EPS (14c) vs ($1.46) last year 05/12/22 Candel Therapeutics reports Q1 EPS (3c), consensus (31c) 10/27/22 Bio-Rad sees FY22 non-GAAP currency-neutral revenue growth at high end of 1%-2% 10/27/22 Bio-Rad reports Q3 EPS $2.60, consensus $2.78 07/28/22 Bio-Rad sees FY22 currency-neutral revenue growth high end of 1%-2% 07/28/22 Bio-Rad reports Q2 adjusted EPS $3.38, consensus $2.80 11/07/22 Amwell sees clear visibility to achieving FY revenue at lower end of guidance 11/07/22 Amwell reports Q3 EPS (25c), consensus (26c) 08/04/22 Amwell backs FY22 revenue view of $275M-$285M, consensus $276.8M 08/04/22 Amwell reports Q2 EPS (25c), consensus (26c) 08/11/22 Absci reports Q2 EPS (32c), consensus (30c) 05/11/22 Absci reports Q1 EPS (33c), consensus (29c)
Recommendations
Barrington analyst Kevin…
Barrington analyst Kevin Steinke raised the firm's price target on Cross Country Healthcare to $45 from $41 and keeps an Outperform rating on the shares. The analyst notes the company's Q3/2022 results exceed recently increased guidance. The demand environment remains favorable due to the extremely tight healthcare labor market, Steinke adds, pointing out that growth also continues to benefit from the significant investments that Cross Country has made in recruiter productivity and capacity.
Show Hide Related Items >> <<
CCRN Cross Country Healthcare 09/14/22 Cross Country Healthcare sees path to $3B in revenue, $300M in EBITDA 09/13/22 Cross Country Healthcare to acquire Mint Medical Physician Staffing, LP 08/16/22 Cross Country Healthcare board authorizes up to $100M share repurchase program CCRN Cross Country Healthcare 10/05/22 Truist Cross Country Healthcare downgraded to Hold at Truist on valuation 10/05/22 Truist Cross Country Healthcare downgraded to Hold from Buy at Truist 09/15/22 Benchmark Cross Country Healthcare price target raised to $42 from $37 at Benchmark 06/17/22 Barrington Cross Country Healthcare shares 'significantly undervalued,' says Barrington CCRN Cross Country Healthcare 11/02/22 Cross Country Healthcare sees Q4 adjusted EPS 85c-95c, consensus 74c 11/02/22 Cross Country Healthcare reports Q3 adjusted EPS $1.07, consensus 95c 09/14/22 Cross Country Healthcare sees Q4 revenue minimum $550M, consensus $519.55M 09/14/22 Cross Country Healthcare sees minimum 2023 revenue $2.2B, consensus $2.07B CCRN Cross Country Healthcare 09/14/22 What You Missed On Wall Street On Wednesday 09/14/22 What You Missed On Wall Street This Morning 08/03/22 Fly Intel: After-Hours Movers
